Scleroderma--developing measures of response

J Rheumatol. 2005 Dec;32(12):2477-80.

Abstract

The scleroderma research community continued its focus on the development and proper validation of the outcome measures for clinical trials in scleroderma during the special interest group meeting at OMERACT 7. Deliberations focused on progress in the assessment of gastrointestinal disease, renal physiology, vascular damage, and the unique challenges inherent in studying pediatric patients with scleroderma.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Child
  • Child, Preschool
  • Clinical Trials as Topic
  • Fingers
  • Gastrointestinal Diseases / etiology
  • Glomerular Filtration Rate
  • Health Status
  • Humans
  • Kidney Diseases / etiology
  • Kidney Diseases / physiopathology
  • Middle Aged
  • Outcome Assessment, Health Care*
  • Quality of Life
  • Research Design
  • Scleroderma, Localized / drug therapy*
  • Scleroderma, Localized / pathology
  • Scleroderma, Systemic / complications
  • Scleroderma, Systemic / drug therapy*
  • Scleroderma, Systemic / physiopathology
  • Skin Ulcer / etiology
  • Skin Ulcer / pathology